

Reply to Llibre et al

TO THE EDITOR—The letter by Llibre et al states that our study lacks a comparison between individual vaccines, so the authors present their own research on this topic, showing superiority of messenger RNA vaccines over adenovirus-based vaccines. We did perform vaccine-specific analyses (see Supplementary Material 2, Sections 11–14) [1], which roughly agree with the findings by Llibre et al; however, due to space limitations, we only briefly mentioned them in the

main text. We also refer interested readers to our previous (preprint) study [1], which analyzes differences in the protection against the Delta variant among individual vaccines in more detail and which has been recently accepted for publication.

Martin Šmíd,¹ Luděk Berec,² and Jan Trnka³

¹Czech Academy of Sciences, Institute of Information Theory and Automation, Prague, Czech Republic; ²Centre for Mathematical Biology, Institute of Mathematics, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic; and ³Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

Reference

1. Berec L, Smid M, Pribylova L, et al. Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view. medRxiv [Preprint]. Posted 12 December 2021. doi:10.1101/2021.12.10.21267590.

Received 22 June 2022; editorial decision 22 June 2022; accepted 22 June 2022; published online 28 June 2022

Correspondence: Martin Šmíd, PhD (smid@utia.cas.cz).

The Journal of Infectious Diseases® 2022;226:941
 © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
<https://doi.org/10.1093/infdis/jiac258>